PRL and pituitary tumor: Considering non-pituitary tumors, overall endocrine deficiencies occurred in 51.5 (±26)% for any axis, 22.8 (±17.5)% for prolactin, 20 (±16.2)% for ACTH, 16.2 (±12.8)% for TSH, 20.7 (±11.2)% for FSH/LH and 33.7 (±29.1)% for GH (Table 1).